Vadadustat Market

Vadadustat API market is projected to grow at a CAGR of 8.50% between 2025 and 2035, primarily driven by factors such as the increasing prevalence of chronic diseases, rising demand for generics, and government initiatives to boost domestic production. Vadadustat, marketed as Vafseo, is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor developed by Akebia Therapeutics. It is primarily used to treat symptomatic anemia associated with chronic kidney disease (CKD), particularly in adult patients undergoing chronic maintenance dialysis. The active pharmaceutical ingredient (API) of Vadadustat is produced by various manufacturers worldwide, including companies in India.

The key segments within the API market include synthetic APIs, biotech APIs, and generic APIs. Synthetic APIs dominate the market due to their cost-effectiveness and widespread use in various therapeutic areas. Biotech APIs are gaining traction, driven by advancements in biotechnology and the growing demand for biologics. Generic APIs continue to expand, fueled by the expiration of patents for several blockbuster drugs and the increasing adoption of generic medications worldwide.

Geographically, Asia-Pacific dominates the vadadustat market, India stands out as a key player in the global API market. The country’s robust pharmaceutical infrastructure, skilled workforce, and favorable government policies have positioned it as a leading producer and exporter of APIs. India supplies a significant portion of the world’s generic drugs, contributing to its prominence in the global API landscape.

Prominent players in the market include Aurobindo Pharma, Lupin Ltd, Viatris Inc., Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd. These companies leverage their extensive manufacturing capabilities, research and development expertise, and global distribution networks to maintain a competitive edge in the market.